17.87
Schlusskurs vom Vortag:
$17.74
Offen:
$17.65
24-Stunden-Volumen:
5.91M
Relative Volume:
0.88
Marktkapitalisierung:
$12.19B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
3.1628
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+8.78%
1M Leistung:
+18.62%
6M Leistung:
+77.69%
1J Leistung:
+53.53%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Vergleichen Sie ROIV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
17.86 | 12.11B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
474.21 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.24 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
841.51 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
INSM
Insmed Inc
|
164.61 | 35.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-02 | Eingeleitet | Citigroup | Buy |
2025-07-10 | Fortgesetzt | Goldman | Buy |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-10-17 | Eingeleitet | Guggenheim | Buy |
2023-06-08 | Eingeleitet | BofA Securities | Neutral |
2022-10-27 | Eingeleitet | JP Morgan | Overweight |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-12-15 | Eingeleitet | Goldman | Buy |
2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
2021-10-28 | Eingeleitet | Citigroup | Buy |
2021-10-26 | Eingeleitet | Cowen | Outperform |
2021-10-26 | Eingeleitet | Jefferies | Buy |
2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) - Insider Monkey
13 Best Growth Stocks Under $25 to Buy Right Now - Insider Monkey
Risk vs reward if holding onto Roivant Sciences Ltd.Wall Street Watch & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for Roivant Sciences Ltd.Weekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
Roivant Sciences Ltd. stock prediction for this weekMarket Performance Report & Weekly Stock Performance Updates - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyDip Buying & Long-Term Growth Stock Strategies - newser.com
Will Roivant Sciences Ltd. (87S) stock outperform benchmarksTrade Signal Summary & Daily Oversold Stock Bounce Ideas - newser.com
Is Roivant Sciences Ltd. (87S) stock a contrarian opportunityMarket Performance Report & Low Drawdown Investment Ideas - nchmf.gov.vn
Is a relief rally coming for Roivant Sciences Ltd. holders2025 AllTime Highs & Verified Momentum Stock Alerts - newser.com
Is Roivant Sciences Ltd. (87S) stock cheap by valuation metrics2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Combining machine learning predictions for Roivant Sciences Ltd.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
This Red-Hot Biopharma Stock Could Fizzle Out Soon - MSN
Can you recover from losses in Roivant Sciences Ltd.Earnings Overview Report & Precise Trade Entry Recommendations - newser.com
(ROIV) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Top chart patterns to watch in Roivant Sciences Ltd.Quarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing The 16% Potential Upside - DirectorsTalk Interviews
Using Ichimoku Cloud for Roivant Sciences Ltd. technicals2025 Trade Ideas & Weekly Setup with ROI Potential - newser.com
How sentiment analysis helps forecast Roivant Sciences Ltd.2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Will Roivant Sciences Ltd. continue its uptrendJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Will Roivant Sciences Ltd. stock gain from government policiesDay Trade & Daily Technical Stock Forecast Reports - newser.com
Is Roivant Sciences Ltd. stock in correction or buying zoneMarket Activity Recap & AI Driven Price Predictions - nchmf.gov.vn
Roivant Sciences president Venker sells $14.5m in shares By Investing.com - Investing.com Nigeria
Roivant Sciences president Venker sells $14.5m in shares - Investing.com
Roivant Sciences Hits New 52-Week High of $17.12, Up 60.59% - Markets Mojo
Roivant Sciences stock hits all-time high at 16.8 USD By Investing.com - Investing.com South Africa
Roivant Sciences stock hits all-time high at 16.8 USD - Investing.com India
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
Roivant Sciences president Venker sells $2m in shares By Investing.com - Investing.com Australia
Roivant Sciences president Venker sells $2m in shares - Investing.com
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Venker Eric | President & Immunovant CEO |
Oct 16 '25 |
Option Exercise |
15.85 |
318,282 |
5,044,770 |
1,823,241 |
Venker Eric | President & Immunovant CEO |
Oct 17 '25 |
Option Exercise |
15.85 |
118,418 |
1,876,925 |
1,623,377 |
Venker Eric | President & Immunovant CEO |
Oct 15 '25 |
Sale |
16.93 |
414,683 |
7,020,583 |
1,504,959 |
Venker Eric | President & Immunovant CEO |
Oct 16 '25 |
Sale |
17.05 |
318,282 |
5,426,708 |
1,504,959 |
Venker Eric | President & Immunovant CEO |
Oct 17 '25 |
Sale |
17.06 |
118,418 |
2,020,211 |
1,504,959 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):